Publications

BibTex format

@article{Banerjee:2016:10.1186/s13063-016-1445-7,
author = {Banerjee, PJ and Cornelius, VR and Phillips, R and Lo, JW and Bunce, C and Kelly, J and Murphy, C and Edwards, RT and Robertson, EL and Charteris, DG},
doi = {10.1186/s13063-016-1445-7},
journal = {Trials},
title = {Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial},
url = {http://dx.doi.org/10.1186/s13063-016-1445-7},
volume = {17},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Eyes sustaining open globe trauma are at high risk of severe visual impairment. Ocular injuries which result in visual loss invariably affect the posterior segment of the eye, and prevention of visual loss involves posterior segment (vitreoretinal) surgery. Despite improvements in vitreoretinal surgical techniques, outcomes in these patients remain unsatisfactory, and development of the intraocular scarring response proliferative vitreoretinopathy is the leading cause. Proliferative vitreoretinopathy is the most common cause of recurrent retinal detachment in these eyes; it is reported to occur in up to 45 % of cases. METHODS/DESIGN: The Adjunctive Steroid Combination in Ocular Trauma (ASCOT) trial is a multi-centre, double-masked, parallel-arm randomised controlled trial with an internal pilot designed to investigate the effectiveness and cost-effectiveness of using intravitreal and sub-Tenon's triamcinolone acetonide peri-operatively in patients undergoing vitrectomy following open globe trauma. In total, 300 eyes of 300 patients will be recruited and randomly allocated to one of two treatment groups. Both groups will receive standard surgical treatment and routine pre-operative and post-operative treatment and care. The treatment group will receive an adjunctive peri-operative steroid combination (triamcinolone acetonide) consisting of 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon's space. The trial incorporates a two-stage internal pilot to examine projected recruitment and retention rates. Progression criteria from the internal pilot study will enable us to determine whether to undertake the main trial. Patients and primary outcome assessors will be masked to treatment allocation. The primary outcome will be an improvement from baseline to 6 months of at least 10 on the corrected visual acuity as measured by ETDRS letter score. Secondary outcomes will be development of scarring, retinal detachme
AU  - Banerjee,PJ
AU  - Cornelius,VR
AU  - Phillips,R
AU  - Lo,JW
AU  - Bunce,C
AU  - Kelly,J
AU  - Murphy,C
AU  - Edwards,RT
AU  - Robertson,EL
AU  - Charteris,DG
DO  - 10.1186/s13063-016-1445-7
PY  - 2016///
SN  - 1745-6215
TI  - Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial
T2  - Trials
UR  - http://dx.doi.org/10.1186/s13063-016-1445-7
UR  - http://hdl.handle.net/10044/1/39104
VL  - 17
ER  -

Download

ProfessorVictoriaCornelius

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)